[1] GHALAMFARSA G, KAZEMI M H, RAOOFI MOHSENI S, et al. CD73 as a potential opportunity for cancer immunotherapy[J]. Expert Opin Ther Targets, 2019, 23(2):127-142.
[2] ZIMMERMANN H. 5'-Nucleotidase:molecular structure and functional aspects[J]. Biochem J, 1992, 285(Sup 2):345-365.
[3] ALLARD D, ALLARD B, GAUDREAU P O, et al. CD73-adenosine:a next-generation target in immuno-oncology[J]. Immunotherapy, 2016, 8(2):145-163.
[4] RESTA R, YAMASHITA Y, THOMPSON L F. Ecto-enzyme and signaling functions of lymphocyte CD73[J]. Immunol Rev, 1998, 161:95-109.
[5] STAGG J, SMYTH M J. Extracellular adenosine triphosphate and adenosine in cancer[J]. Oncogene, 2010, 29(39):5346-5358.
[6] TOCZEK M, PIERZYNOWSKA K, KUTRYB-ZAJAC B, et al. Characterization of adenine nucleotide metabolism in the cellular model of Huntington's disease[J]. Nucleosides Nucleotides Nucleic Acids, 2018, 37(11):630-638.
[7] ZHI X, WANG Y, ZHOU X, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells[J]. Cancer Sci, 2010, 101(12):2561-2569.
[8] SAMANTA D, PARK Y, NI X H, et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells[J]. Proc Natl Acad Sci USA, 2018, 115(6):E1239-E1248.
[9] ALLARD D, ALLARD B, GAUDREAU P O, et al. CD73-adenosine:a next-generation target in immuno-oncology[J]. Immunotherapy, 2016, 8(2):145-163.
[10] WANG L, TANG S, WANG Y, et al. Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis[J]. Clin Exp Metastasis, 2013, 30(5):671-680.
[11] LEY K. Plugging the leaks[J]. Nat Med, 2001, 7(10):1105-1106.
[12] COMERFORD K M, LAWRENCE D W, SYNNESTVEDT K, et al. Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability[J]. FASEB J, 2002, 16(6):583-585.
[13] TURCOTTE M, ALLARD D, MITTAL D, et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy[J]. Cancer Res, 2017, 77(20):5652-5663.
[14] PENG D, HU Z, WEI X, et al. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer[J]. IUBMB Life, 2019, 71(1):113-124.
[15] NEVEDOMSKAYA E, PERRYMAN R, SOLANKI S, et al. A systems oncology approach identifies NT5E as a key metabolic regulator in tumor cells and modulator of platinum sensitivity[J]. J Proteome Res, 2016, 15(1):280-290.
[16] AIRAS L, HELLMAN J, SALMI M, et al. CD73 is involved in lymphocyte binding to the endothelium:characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73[J]. J Exp Med, 1995, 182(5):1603-1608.
[17] SADEJ R, SPYCHALA J, SKLADANOWSKI A C. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma[J]. Melanoma Res, 2006, 16(3):213-222.
[18] ZHI X, WANG Y, YU J, et al. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer[J]. IUBMB Life, 2012, 64(11):911-920.
[19] BUSSOLATI B, LAURITANO C, MOGGIO A, et al. Renal CD133+/CD73+ progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition[J]. J Am Soc Nephrol, 2013, 24(8):1234-1241.
[20] NIEMELÄ J, HENTTINEN T, YEGUTKIN G G, et al. IFN-alpha induced adenosine production on the endothelium:a mechanism mediated by CD73(ecto-5'-nucleotidase) up-regulation[J]. J Immunol, 2004, 172(3):1646-1653.
[21] YAMASHITA Y, HOOKER S W, JIANG H, et al. CD73 expression and Fyn-dependent signaling on murine lymphocytes[J]. Eur J Immunol, 1998, 28(10):2981-2990.
[22] FAUSTHER M, SHEUNG N, SAIMAN Y, et al. Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(8):G904-G914.
[23] MAZUMDER B, SESHADRI V, FOX P L. Translational control by the 3'-UTR:the ends specify the means[J]. Trends Biochem Sci, 2003, 28(2):91-98.
[24] WANG N, XIANG X H, CHEN K, et al. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma[J]. Biochimie, 2018, 146:56-67.
[25] BONNIN N, ARMANDY E, CARRAS J, et al. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma[J]. Oncotarget, 2016, 7(28):44023-44038.
[26] SCIARAFFIA E, RICCOMI A, LINDSTEDT R, et al. Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors[J]. J Leukoc Biol, 2014, 96(1):113-122.
[27] YANG X, PEI S, WANG H, et al. Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73[J]. BMC Cancer, 2017, 17(1):255.
[28] TERP M G, OLESEN K A, ARNSPANG E C, et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells[J]. J Immunol, 2013, 191(8):4165-4173.
[29] STAGG J, DIVISEKERA U, MCLAUGHLIN N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis[J]. Proc Natl Acad Sci USA, 2010, 107(4):1547-1552.
[30] ANTONIOLI L, YEGUTKIN G G, PACHER P, et al. Anti-CD73 in cancer immunotherapy:awakening new opportunities[J]. Trends Cancer, 2016, 2(2):95-109. |
